MYNZ Mainz Biomed
- 0.740
- +0.003+0.45%
- 0.766
- +0.026+3.47%
Mainz Biomed News
MRNA Is Promising A Breakthrough In Fighting Cancer
When it comes to cancer, there's innovation both on the diagnostics and the treatment front thanks to messenger RNA, or mRNA, a genetic material we all got acquainted with during the COVID-19 era as i
Mainz Biomed Reports Positive Topline Results From Pooled Study Evaluating Novel MRNA Biomarkers and Proprietary AI Algorithm for Integration Into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic
Groundbreaking topline results demonstrated sensitivity for colorectal cancer of 92% with specificity of 90% and best-in-class sensitivity for advanced adenoma of 82%690 subjects analyzed including previously unexamined
Mainz Biomed Announces Upcoming Annual Meeting
Mainz Biomed Secures New Funding Agreement
Cantor Fitzgerald Inc.: Mainz Biomed (MYNZ.US) neutral rating confirmed.
Cantor Fitzgerald Inc.: Mainz Biomed (MYNZ.US) neutral rating confirmed.
Cantor Fitzgerald Reiterates Neutral on Mainz Biomed
Cantor Fitzgerald analyst Ross Osborn reiterates Mainz Biomed (NASDAQ:MYNZ) with a Neutral.
Analysts' Top Healthcare Picks: Mainz Biomed B.V. (MYNZ), Century Therapeutics (IPSC)
Mainz Biomed B.V. Confronts Escalating Cybersecurity Dangers Threatening Operations and Data Security
Mainz Biomed (MYNZ.US): The 2023 Q4 financial report achieved revenue of US$2147.6 million, with an expected value of US$270,000; earnings per share of -0.24 dollars, with an expected value of -0.32 dollars.
Mainz Biomed (MYNZ.US): The 2023 Q4 financial report achieved revenue of US$2147.6 million, with an expected value of US$270,000; earnings per share of -0.24 dollars, with an expected value of -0.32 dollars.
Mainz Biomed 2023 Rev $895,500 >MYNZ
Mainz Biomed 2023 Rev $895,500 >MYNZ
Press Release: Mainz Biomed Reports Full Year 2023 Financial Results
Mainz Biomed Reports Full Year 2023 Financial Results ColoAlert(R) Revenue Increased 69% Year Over Year; Net Loss in Line with Previous Year; Cash Balance at Year End of $7.1 Million BERKELEY, Calif
Pharma's Post-Pandemic Story To Unlock A Cancer-Free Era
Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) did not only earn billions of dollars from their COVID-19 leading products but also rose to fame for saving the world from an unforeseen pandemic. But, in a
Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment
BERKELEY, Calif. and MAINZ, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a leader in molecular genetics diagnostic solutions for early cancer detection,
Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options
BERKELEY, Calif. and MAINZ, Germany, March 18, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a leader in molecular genetics diagnostic solutions for early cancer detection,
Mainz Biomed Presents ColoAlert at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations
BERKELEY, Calif. and MAINZ, Germany, March 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a leader in molecular genetics diagnostic solutions for early cancer detection,
Mainz Biomed Is Maintained at Buy by HC Wainwright & Co.
Mainz Biomed Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on Mainz Biomed, Lowers Price Target to $3
HC Wainwright & Co. analyst Yi Chen maintains Mainz Biomed with a Buy and lowers the price target from $5 to $3.
Mainz Biomed Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/06/2024 215.29% HC Wainwright & Co. $5 → $3 Maintains Buy 11/21/2023 — Cantor Fitzgerald Downgrades Ov
Analysts Are Bullish on Top Healthcare Stocks: Iterum Therapeutics (ITRM), Mainz Biomed B.V. (MYNZ)
Mainz Biomed Partners With Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic
Dr. Jay Wohlgemuth, former Chief Medical & Scientific Officer of Quest Diagnostics and Dr. Ray Tabibiazar, a seasoned industry executive, to lead collaborationMainz Biomed's Pivotal FDA PMA clinical trial
Analysis
Price Target
No Data
